John Öhd
Chief Executive Officer chez MODUS THERAPEUTICS HOLDING AB
Profil
John Öhd occupies the position of Chief Executive Officer of Modus Therapeutics Holding AB, Chief Executive Officer at Modus Therapeutics AB (a subsidiary of Modus Therapeutics Holding AB) and Chief Scientific Officer & Venture Partner at Karolinska Development AB.
He is also on the board of Umecrine Cognition AB, Svenska Vaccinfabriken Produktion AB and AnaCardio AB.
In the past Dr. Öhd held the position of Chief Medical Officer of Medivir AB, Group Director-Development at AstraZeneca AB and Senior Director-Experimental Medicine at Shire Sweden AB.
He received a doctorate from the University of Linköping and a doctorate from the University of Lund.
Postes actifs de John Öhd
Sociétés | Poste | Début |
---|---|---|
KAROLINSKA DEVELOPMENT AB | Chief Tech/Sci/R&D Officer | 01/06/2020 |
MODUS THERAPEUTICS HOLDING AB | Chief Executive Officer | 01/01/2020 |
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Chief Executive Officer | - |
Svenska Vaccinfabriken Produktion AB
Svenska Vaccinfabriken Produktion AB BiotechnologyHealth Technology Svenska Vaccinfabriken Produktion AB develops vaccines and immunotherapies to prevent and treat life-threatening diseases. The company is based in Stockholm, Sweden. The Swedish company was founded by Matti Sällberg, Margaret Chen, Jens Bäck, Lars Frelin. Richard Bethell has been the CEO of the company since 2022. | Director/Board Member | - |
Umecrine Cognition AB
Umecrine Cognition AB Pharmaceuticals: MajorHealth Technology Umecrine Cognition AB develops pharmaceuticals against neurological disorders in the central nervous system. The firm focuses on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. The company was founded by Torbjörn Bäckström in 2006 and is headquartered in Solna, Sweden. | Director/Board Member | - |
AnaCardio AB
AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | Director/Board Member | - |
Anciens postes connus de John Öhd
Sociétés | Poste | Fin |
---|---|---|
MEDIVIR AB | Chief Tech/Sci/R&D Officer | 15/07/2018 |
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Corporate Officer/Principal | - |
Shire Sweden AB | Corporate Officer/Principal | - |
Formation de John Öhd
University of Linköping | Doctorate Degree |
University of Lund | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 3 |
---|---|
MEDIVIR AB | Health Technology |
KAROLINSKA DEVELOPMENT AB | Finance |
MODUS THERAPEUTICS HOLDING AB | Health Technology |
Entreprise privées | 6 |
---|---|
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Commercial Services |
Umecrine Cognition AB
Umecrine Cognition AB Pharmaceuticals: MajorHealth Technology Umecrine Cognition AB develops pharmaceuticals against neurological disorders in the central nervous system. The firm focuses on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. The company was founded by Torbjörn Bäckström in 2006 and is headquartered in Solna, Sweden. | Health Technology |
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Health Technology |
Svenska Vaccinfabriken Produktion AB
Svenska Vaccinfabriken Produktion AB BiotechnologyHealth Technology Svenska Vaccinfabriken Produktion AB develops vaccines and immunotherapies to prevent and treat life-threatening diseases. The company is based in Stockholm, Sweden. The Swedish company was founded by Matti Sällberg, Margaret Chen, Jens Bäck, Lars Frelin. Richard Bethell has been the CEO of the company since 2022. | Health Technology |
Shire Sweden AB | |
AnaCardio AB
AnaCardio AB Pharmaceuticals: MajorHealth Technology AnaCardio AB is a clinical stage biopharmaceutical company based in Stockholm, Sweden. AnaCardio develops drugs targeting a novel mechanism that improves cardiac contractility to treat heart failure, a progressive cardiac syndrome affecting more than six million individuals in the US and nearly 100 million worldwide. The Swedish company's unique solution is based on the ghrelin signaling pathway, intended to increase contractility without causing adverse tachycardia, arrhythmia, ischemia, or hypotension. The company was founded by Lars Lund and is currently led by CEO Patrik Strömberg since 2021. | Health Technology |